In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Christopher Locher, Chief Executive Officer at Versatope Therapeutics, about the current landscape for vaccine manufacturers and innovators. Their conversation covers vaccine platform development, financing challenges for infectious disease companies, policy and regulatory uncertainty, the public health implications of changes to childhood immunization schedules, and the steps needed to rebuild trust in vaccination. Key Topics: Vaccine Platform Innovation: Nanoparticle technology, universal influenza vaccine development, multispecific targeting, infectious disease, and oncology applications. Financing Challenges: Venture capital headwinds, NIH support, clinical development costs, grant cancellations, and startup survival pressures. Policy Uncertainty: Changes to childhood immunization schedules, liability debates, academic licensing concerns, royalty proposals, and the biotech investment climate. Public Health Risks: Vaccine access, childhood disease vulnerability, antimicrobial resistance, influenza complications, and consequences of fragmented immunization policy. Trust Rebuilding: COVID backlash, transparency concerns, anti-science sentiment, provider-patient communication, rebuilding confidence in vaccines. Opinions expressed are those of the speakers.See omnystudio.com/listener for privacy information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related